Get the Stockscreener App
1.23
0.79%
-0.03
NanoViricides Inc stock is traded at $1.23, with a volume of 34,618.
It is down -0.79% in the last 24 hours and down -18.30% over the past month.
NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of viral infections. The company is developing anti-influenza drug candidates at pre-clinical and advanced pre-clinical stage, which include two FluCide drugs, such as NV-INF-2, an oral anti-influenza drug and NV-INF-1, an injectable anti-influenza drug for H7N9, Bird Flu H5N1, and other Highly Pathogenic Influenzas; and HIVCide, an anti-human immunodeficiency virus (HIV) drug candidate that could provide functional cure for HIV/AIDS. It is also developing HerpeCide, a skin cream or gel formulation for the treatment of oral and genital herpes virus infections; and eye drops against viral infections of the external eye, as well as involved in the other research programs against Rabies virus, Ebola, and Marburg viruses. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
See More
Previous Close:
$1.26
Open:
$1.25
24h Volume:
34,618
Relative Volume:
0.14
Market Cap:
$22.14M
Revenue:
-
Net Income/Loss:
$-8.29M
P/E Ratio:
-1.7571
EPS:
-0.7
Net Cash Flow:
$-6.47M
1W Performance:
-1.57%
1M Performance:
-18.30%
6M Performance:
-24.70%
1Y Performance:
-9.42%
1-Day Range:
$1.23
$1.27
1-Week Range:
$1.16
$1.29
52-Week Range:
$0.94
$2.2299
NanoViricides Inc Stock (NNVC) Company Profile
Name
NanoViricides Inc
Sector
Industry
Phone
203-937-6137
Address
1 Controls Drive, Shelton, CT
Compare NNVC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NNVC
NanoViricides Inc
|
1.2301 | 22.68M | 0 | -8.29M | -6.47M | -0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
430.88 | 109.65B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.80 | 82.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
455.03 | 58.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
910.63 | 56.50B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.13 | 43.62B | 447.02M | -1.18B | -906.14M | -6.1812 |
NanoViricides Inc Stock (NNVC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-11-15 | Initiated | Midtown Partners | Strong Buy |
NanoViricides Inc Stock (NNVC) Latest News
What drives NanoViricides Inc stock priceAnalyst Downgrades & Free Superior Stock Performance - earlytimes.in
NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd - St. Cloud Times
NanoViricides Holds 2025 Annual Stockholders Meeting - TipRanks
NanoViricides Dual Track Clinical Strategy Explained by a Research ReportBroad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute Respiratory Infections of All Viruses - Livingston Daily
NanoViricides, Inc. Has Filed its Quarterly ReportSubsequent Raise Has Fortified Fiscal Position - The Marion Star
NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value - Canton Daily Ledger
Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive - Bluffton Today
NanoViricides to Present at the PODD 2025 Conference in Boston on October 27 - York Daily Record
Why NanoViricides Inc. (NV3P) stock stays resilient2025 Stock Rankings & Precise Swing Trade Entry Alerts - newser.com
Why NanoViricides Inc. stock stays resilientPortfolio Value Report & Technical Confirmation Trade Alerts - newser.com
Will NanoViricides Inc. stock recover faster than industryJuly 2025 Momentum & Risk Adjusted Swing Trade Ideas - newser.com
Why NanoViricides Inc. stock is trending on social media2025 Market Overview & Safe Entry Point Identification - newser.com
Will NanoViricides Inc. stock continue upward momentumJuly 2025 PreEarnings & Free Fast Entry Momentum Trade Alerts - newser.com
Can NanoViricides Inc. (NV3P) stock ride next bull market cycleWeekly Trade Analysis & Weekly High Conviction Ideas - newser.com
Is NanoViricides Inc. (NV3P) stock supported by free cash flow2025 Market Outlook & Growth Focused Investment Plans - newser.com
NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo - Erie Times-News
Will NanoViricides Inc. stock sustain bullish trend into 20252025 Year in Review & Technical Confirmation Trade Alerts - newser.com
Is NanoViricides Inc. (NV3P) stock a good hedge against inflationTrade Volume Report & Weekly Setup with ROI Potential - newser.com
Will NanoViricides Inc. stock boost dividends furtherMarket Risk Summary & Community Consensus Picks - newser.com
Is NanoViricides Inc. stock a buy before product launchesJuly 2025 Trends & Free Real-Time Market Sentiment Alerts - newser.com
Published on: 2025-11-19 20:46:00 - newser.com
Why institutional investors increase stakes in NanoViricides Inc. (NV3P) stockEarnings Risk Report & Risk Controlled Swing Trade Alerts - newser.com
How NanoViricides Inc. stock trades after earnings2025 Year in Review & Expert-Curated Trade Recommendations - newser.com
NanoViricides Inc Stock (NNVC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.18%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):